Urothelial Carcinoma Treatment Market Research Report – Forecast to 2027

Urothelial Carcinoma Treatment Market Research Report: By Types (Non-Invasive & Invasive Urothelial Carcinoma), by Treatment (Immunotherapy, Radiotherapy, Chemotherapy), by End-User (Hospital Pharmacy, Retail Pharmacy, Others) – Forecast Till 2027

ID: MRFR/Pharma/4983-HCR | February 2021 | Region: Global | 100 pages

Urothelial Carcinoma Treatment Market Scenario:


Urothelial carcinoma treatment market is expected to grow over the forecast period of 2023 and is expected to register a CAGR ~7.8% during the forecast period of 2018–2023.

Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar cancer in other parts of the urinary tract. Hence the market is expected to grow due to increasing prevalence of bladder cancer. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, it is expected to boost the market during the forecast period.  

Various factors that can hamper the growth of the market are the presence of the generic drug in the market and the high cost of R&D investment for the development of a new drug for treatment.

Urothelial Carcinoma Treatment Market Segmentation

The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users. Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment. On basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy. Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.

Urothelial Carcinoma Treatment Market Key players


  • GlaxoSmithKline plc

  • Genentech, Inc

  • Novartis AG

  • Dendreon

  • Merck KGaA

  • Eisai Co

  • Sanofi S.A

  • Bristol-Myers Squibb


Regional Market Summary  

Global Urothelial Carcinoma Treatment Market Share (%), by Region, 2017


Urothelial Carcinoma Treatment Market Share


Source: Centers for Disease Control and Prevention (CDC)


On a regional basis, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.


Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia-Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.


The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.


Global Urothelial Carcinoma Treatment Market, by Type



  • Non-invasive urothelial carcinoma treatment

  • Invasive urothelial carcinoma treatment


Global Urothelial Carcinoma Treatment Market, by Treatment



  • Immunotherapy

  • Radiotherapy

  • Chemotherapy


Global Urothelial Carcinoma Treatment Market, by End-User



  • Hospital pharmacy

  • Retail pharmacy

  • Others


Global Urothelial Carcinoma Treatment Market, by Region


Americas

  • North America

  • US

  • Canada

  • South America


Europe

  • Western Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia-Pacific


Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Hospitals and clinics

  • Laboratories and associations



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2018-2023: 7.8%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Treatment, And End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb
  Key Market Opportunities   Investment in R&D activities to come up with new cancer treatment
  Key Market Drivers   Growing prevalence of cancer


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Urothelial Carcinoma, also known as transitional cell carcinoma, is a cancer of the urinary bladder that can spread to other parts of the body.

Urothelial Carcinoma is expected to exhibit a strong 7.8% CAGR over the forecast period from 2020 to 2027.

Growing prevalence of cancer is the major driver for the market.

Americas hold the largest share in the global Urothelial Carcinoma Market.

Leading players in the Urothelial Carcinoma Market include Sanofi, Genentech, and Novartis, among others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Urothelial Carcinoma Treatment Market, by Types

6.1 Introduction

6.2 Non-invasive Urothelial Carcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Invasive Urothelial Carcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Urothelial Carcinoma Treatment Market, by Treatment

7.1 Introduction

7.2 Immunotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Radiotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Urothelial Carcinoma Treatment Market, by End-User

8.1 Introduction

8.2 Hospital Pharmacy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Retail Pharmacy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Urothelial Carcinoma Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 GlaxoSmithKline plc

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Genentech, Inc

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Dendreon

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Merck KGaA

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Eisai Co

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Sanofi S.A

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Bristol-Myers Squibb

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Urothelial Carcinoma Treatment Industry

Chapter 13. Appendix

 

LIST OF TABLES

Table 1 Global Urothelial Carcinoma Treatment Market Synopsis, 2020–2027

Table 2 Global Urothelial Carcinoma Treatment Market Estimates and Forecast, 2020–2027

(USD Million)

Table 3 Global Urothelial Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 4 Global Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD Million)

Table 5 Global Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027(USD Million)

Table 6 Global Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 7 North America: Global Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD

Million)

Table 8 North America: Global Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 9 North America: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 10 US: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD Million)

Table 11 US: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 12 US: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 13 Canada: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD Million)

Table 14 Canada: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 15 Canada: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 16 South America: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD

Million)

Table 17 South America: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 18 South America: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 19 Europe: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD Million)

Table 20 Europe: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 21 Europe: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 22 Western Europe: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD

Million)

Table 23 Western Europe: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 24 Western Europe: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 25 Eastern Europe: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD

Million)

Table 26 Eastern Europe: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 27 Eastern Europe: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027(USD Million)

Table 28 Asia-Pacific: Urothelial Carcinoma Treatment Market, by Types, 2020–2027 (USD

Million)

Table 29 Asia-Pacific: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 30 Asia-Pacific: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 31 Middle East & Africa: Urothelial Carcinoma Treatment Market, by Types, 2020–2027

(USD Million)

Table 32 Middle East & Africa: Urothelial Carcinoma Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 33 Middle East & Africa: Urothelial Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

 


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Urothelial Carcinoma Treatment Market

Figure 3 Segmentation Market Dynamics for Global Urothelial Carcinoma Treatment Market

Figure 4 Global Urothelial Carcinoma Treatment Market Share, By Types, 2020

Figure 5 Global Urothelial Carcinoma Treatment Market Share, By Treatment, 2020

Figure 6 Global Urothelial Carcinoma Treatment Market Share, By End-User, 2020

Figure 7 Global Urothelial Carcinoma Treatment Market Share, By Region, 2020

Figure 8 North America: Global Urothelial Carcinoma Treatment Share, By Country, 2020

Figure 9 Europe: Global Urothelial Carcinoma Treatment Share, By Country, 2020

Figure 10 Asia-Pacific: Global Urothelial Carcinoma Treatment Share, By Country, 2020

Figure 11 Middle East & Africa: Global Urothelial Carcinoma Treatment Share, By Country, 2020

Figure 12 Global Urothelial Carcinoma Treatment Share: Company Share Analysis, 2020 (%)

Figure 13 GlaxoSmithKline plc.: Key Financials

Figure 14 GlaxoSmithKline plc.: Segmental Revenue

Figure 15 GlaxoSmithKline plc.: Geographical Revenue

Figure 16 Genentech: Key Financials

Figure 17 Genentech: Segmental Revenue

Figure 18 Genentech: Geographical Revenue

Figure 19 Novartis AG: Key Financials

Figure 20 Novartis AG: Segmental Revenue

Figure 21 Novartis AG: Geographical Revenue

Figure 22 Dendreon: Key Financials

Figure 23 Dendreon: Segmental Revenue

Figure 24 Dendreon: Geographical Revenue

Figure 25 Merck KGaA: Key Financials

Figure 26 Merck KGaA: Segmental Revenue

Figure 27 Merck KGaA: Geographical Revenue

Figure 28 Eisai Co: Key Financials

Figure 29 Eisai Co: Segmental Revenue

Figure 30 Eisai Co: Geographical Revenue

Figure 31 Sanofi S.A: Key Financials

Figure 32 Sanofi S.A: Segmental Revenue

Figure 33 Sanofi S.A: Geographical Revenue

Figure 34 Bristol-Myers Squibb: Key Financials

Figure 35 Bristol-Myers Squibb: Segmental Revenue

Figure 36 Bristol-Myers Squibb: Geographical Revenue